2023
Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration
Gordon A, Saxon A, Kertesz S, Wyse J, Manhapra A, Lin L, Chen W, Hansen J, Pinnell D, Huynh T, Baylis J, Cunningham F, Ghitza U, Bart G, Yu H, Sauer B. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug And Alcohol Dependence 2023, 248: 109902. PMID: 37196572, PMCID: PMC10875624, DOI: 10.1016/j.drugalcdep.2023.109902.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Health AdministrationUse disordersHealth AdministrationOpioid use disorder treatmentHalf of patientsOpen cohort studyRetention of patientsCourse of careUse disorder treatmentLarge healthcare systemCohort studyMedian durationPatient characteristicsPatient demographicsDaily doseMedication treatmentBuprenorphine useClinical dataWhite racePatientsProportion daysDisorder treatmentMultiple coursesHealthcare system
2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisorders
2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors
Gordon K, Manhapra A, Crystal S, Dziura J, Edelman E, Skanderson M, Kerns R, Justice A, Tate J, Becker W. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug And Alcohol Dependence 2020, 216: 108291. PMID: 33011662, PMCID: PMC7644145, DOI: 10.1016/j.drugalcdep.2020.108291.Peer-Reviewed Original ResearchConceptsMorphine equivalent daily doseCause mortalityLong-term opioid therapyTime-updated Cox regressionStrong dose-response relationshipUnnatural deathsEquivalent daily doseDose-response relationshipOpioid doseOpioid therapyUninfected patientsOpioid useDaily doseCox regressionMortality outcomesTherapy doseHigh doseMale veteransOverdose fatalitiesOverdose mortalityPLWHMortalityHIVPatientsDoseAssociations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation
Oliva E, Bowe T, Manhapra A, Kertesz S, Hah J, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon A, Trafton J. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. The BMJ 2020, 368: m283. PMID: 32131996, PMCID: PMC7249243, DOI: 10.1136/bmj.m283.Peer-Reviewed Original ResearchConceptsLength of treatmentVeterans Health AdministrationOpioid treatmentHealth AdministrationLong patientsObservational evaluationRisk of deathHazards regression modelsFocus of guidelinesLong-term useOpioid cessationOpioid prescriptionsOpioid analgesicsOutpatient prescriptionsPlace patientsSafe prescribingPatient deathUS veteransNon-proportional hazards regression modelsPatient's perspectiveFiscal year 2014OpioidsPatientsOverdoseGreater riskNonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis
Kertesz S, Manhapra A, Gordon A. Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis. The Journal Of Law, Medicine & Ethics 2020, 48: 259-267. PMID: 32631183, PMCID: PMC7938366, DOI: 10.1177/1073110520935337.Peer-Reviewed Original Research
2005
Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002
Vaccarino V, Rathore SS, Wenger NK, Frederick PD, Abramson JL, Barron HV, Manhapra A, Mallik S, Krumholz HM. Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002. New England Journal Of Medicine 2005, 353: 671-682. PMID: 16107620, PMCID: PMC2805130, DOI: 10.1056/nejmsa032214.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAspirinBlack PeopleCoronary AngiographyFemaleHealth Services AccessibilityHospital MortalityHumansLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPlatelet Aggregation InhibitorsProcess Assessment, Health CareQuality of Health CareRisk FactorsSex FactorsUnited StatesWhite PeopleConceptsUse of aspirinMyocardial infarctionReperfusion therapyCoronary angiographyRacial differencesTreatment of patientsHospital deathHospital mortalityMultivariable adjustmentUnadjusted analysesNational registryInfarctionWhite womenAspirinAngiographyTherapyWhite menSexPatientsBlack womenSex differencesParticular treatmentBlack menWomenDeath